0000950170-24-138086.txt : 20241218 0000950170-24-138086.hdr.sgml : 20241218 20241218194134 ACCESSION NUMBER: 0000950170-24-138086 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241216 FILED AS OF DATE: 20241218 DATE AS OF CHANGE: 20241218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quisel John D CENTRAL INDEX KEY: 0001586788 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 241560643 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Disc Medicine, Inc. CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 674-9274 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE DATE OF NAME CHANGE: 20210209 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 ownership.xml 4 X0508 4 2024-12-16 0001816736 Disc Medicine, Inc. IRON 0001586788 Quisel John D C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 true true false false Chief Executive Officer true Common Stock 2024-12-16 4 M false 12791 1.01 A 84856 D Common Stock 2024-12-16 4 S false 219 64.6586 D 84637 D Common Stock 2024-12-16 4 S false 5767 65.5789 D 78870 D Common Stock 2024-12-16 4 S false 6305 66.3539 D 72565 D Common Stock 2024-12-16 4 S false 500 67.198 D 72065 D Stock Option (Right to Buy) 1.01 2024-12-16 4 M false 12791 0 D 2030-03-10 Common Stock 12791 225420 D The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.04 to $65.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.04 to $66.03, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.04 to $67.01, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.04 to $67.54, inclusive. The shares underlying this option are fully vested and exercisable as of the date hereof. By: /s/ Rahul Khara, as Attorney-in-Fact 2024-12-18